Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ACIU Stock Forecast 2026-2027
$2.36
Current Price
$245.27M
Market Cap
Buy 4
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to ACIU Price Targets
+409.0%
To High Target of $12.01
+253.8%
To Median Target of $8.35
+129.2%
To Low Target of $5.41
ACIU Price Momentum
-1.3%
1 Week Change
+0.9%
1 Month Change
+14.0%
1 Year Change
-24.8%
Year-to-Date Change
-41.0%
From 52W High of $4.00
+18.0%
From 52W Low of $2.00
📊 TOP ANALYST CALLS
Did ACIU Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if AC Immune is one of their latest high-conviction picks.
Latest ACIU Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, ACIU has a bullish consensus with a median price target of $8.35 (ranging from $5.41 to $12.01). The overall analyst rating is Strong Buy (10.0/10). Currently trading at $2.36, the median forecast implies a 253.8% upside. This outlook is supported by 4 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ACIU Analyst Ratings
4
Buy
0
Hold
0
Sell
ACIU Price Target Range
Low
$5.41
Average
$8.35
High
$12.01
Current: $2.36
Latest ACIU Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ACIU.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 4, 2026 | BTIG | Thomas Shrader | Buy | Reiterates | $8.00 |
| Mar 16, 2026 | BTIG | Buy | Reiterates | $N/A | |
| Nov 4, 2025 | BTIG | Buy | Reiterates | $N/A | |
| Sep 8, 2025 | BTIG | Buy | Reiterates | $N/A | |
| May 1, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Apr 3, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Apr 3, 2025 | HC Wainwright& Co. | Buy | Reiterates | $N/A | |
| Mar 14, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Nov 15, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Nov 6, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Sep 18, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| May 31, 2024 | BTIG | Buy | Initiates | $N/A | |
| Mar 15, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Nov 13, 2023 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Aug 7, 2023 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jun 28, 2023 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| May 1, 2023 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Apr 19, 2023 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Mar 17, 2023 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jul 11, 2022 | SVB Leerink | Outperform | Maintains | $N/A |
AC Immune SA (ACIU) Competitors
The following stocks are similar to AC Immune based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
AC Immune SA (ACIU) Financial Data
AC Immune SA has a market capitalization of $245.27M with a P/E ratio of -3.4x. The company generates $4.59M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is +13.0% quarter-over-quarter, while maintaining an operating margin of -1,321.5% and return on equity of -104.8%.
Valuation Metrics
Market Cap
$245.27M
Enterprise Value
$212.14M
P/E Ratio
-3.4x
PEG Ratio
0.2x
Price/Sales
67.1x
Growth & Margins
Revenue Growth (YoY)
+13.0%
Gross Margin
N/A
Operating Margin
-1,321.5%
Net Margin
0.0%
EPS Growth
+13.0%
Financial Health
Cash/Price Ratio
+32.1%
Current Ratio
0.9x
Debt/Equity
13.6x
ROE
-104.8%
ROA
-23.1%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
AC Immune SA (ACIU) Business Model
About AC Immune SA
What They Do
Develops therapies for neurodegenerative diseases.
Business Model
The company generates revenue by developing and partnering on therapeutic and diagnostic products for neurodegenerative diseases, leveraging its proprietary technology platforms to create innovative solutions. Its collaborations with major pharmaceutical firms help to fund research and advance its pipeline of clinical-stage candidates.
Additional Information
AC Immune SA has a diversified pipeline with several candidates at various stages of development, focusing on conditions like Alzheimer’s and Parkinson’s disease. The company was founded in 2003 and is located in Lausanne, Switzerland, positioning itself as a key player in the biopharmaceutical sector addressing neurodegeneration.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
90
CEO
Dr. Andrea Pfeifer Ph.D.
Country
Switzerland
IPO Year
2016
Website
www.acimmune.comAC Immune SA (ACIU) Latest News & Analysis
Latest News
AC Immune to Showcase Neurodegenerative Disease Pipeline with Three Presentations at AAIC® 2026
9 days ago
Quick Summary
AC Immune (NASDAQ: ACIU) will present its neurodegenerative disease pipeline at the AAIC 2026 in London, showcasing its Morphomer®-based small molecule therapeutics and imaging assets.
Why It Matters
AC Immune's showcase at AAIC 2026 highlights advancements in neurodegenerative treatments, potentially validating its pipeline and influencing stock performance and investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
AC Immune (NASDAQ: ACIU) reported positive interim 12-month data from its Phase 1b/2 ABATE trial of ACI-24 for prodromal Alzheimer's disease, showing safety and antibody response across initial cohorts.
Why It Matters
Positive interim data from AC Immune's trial may indicate a promising treatment for Alzheimer's, potentially boosting the company's stock and attracting investor interest in neurodegenerative therapies.
Source: GlobeNewsWire
Market Sentiment:
Neutral
AC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson's Disease
1 month ago
Quick Summary
AC Immune will receive a $4M grant from the Goradia Family to extend Part 1 of the Phase 2 VacSYn trial for ACI-7104 in Parkinson's disease, assessing safety and efficacy for 2 more years. Final data expected in H2 2026.
Why It Matters
The $4 million grant for AC Immune's ACI-7104 trial signals potential for long-term growth in Parkinson's treatments, enhancing investor confidence in the company's prospects and stock value.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
AC Immune (ACIU) shows a hammer chart pattern, suggesting support after recent losses. Increased earnings estimate revisions may indicate a potential trend reversal.
Why It Matters
AC Immune's hammer chart pattern and positive earnings revisions suggest a potential trend reversal, signaling a buying opportunity and improved investor sentiment.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
AC Immune's Phase 1 trial data for PET tracer ACI-19626 shows higher uptake in ALS patients, indicating potential for early diagnosis in neurodegenerative diseases. Results presented at the 2026 TDP43 Summit.
Why It Matters
AC Immune's promising Phase 1 data on ACI-19626 enhances its position in neurodegenerative disease diagnostics, potentially boosting its market value and attracting investment interest.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
The Davos Alzheimer's Collaborative honors Andrea Pfeifer, retiring CEO of AC Immune, for her impactful work in Alzheimer's policy, research, and care.
Why It Matters
Leadership changes in biotech firms impact innovation strategies and partnerships. Pfeifer's retirement could influence AC Immune's direction in Alzheimer's research, affecting stock performance and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About ACIU Stock
What is AC Immune SA's (ACIU) stock forecast for 2027?
Based on our analysis of 2 Wall Street analysts, AC Immune SA (ACIU) has a median price target of $8.35. The highest price target is $12.01 and the lowest is $5.41.
Is ACIU stock a good investment in 2027?
According to current analyst ratings, ACIU has 4 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $2.36. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ACIU stock?
Wall Street analysts predict ACIU stock could reach $8.35 in the next 12 months. This represents a 253.8% increase from the current price of $2.36. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is AC Immune SA's business model?
The company generates revenue by developing and partnering on therapeutic and diagnostic products for neurodegenerative diseases, leveraging its proprietary technology platforms to create innovative solutions. Its collaborations with major pharmaceutical firms help to fund research and advance its pipeline of clinical-stage candidates.
What is the highest forecasted price for ACIU AC Immune SA?
The highest price target for ACIU is $12.01 from at , which represents a 409.0% increase from the current price of $2.36.
What is the lowest forecasted price for ACIU AC Immune SA?
The lowest price target for ACIU is $5.41 from at , which represents a 129.2% increase from the current price of $2.36.
What is the overall ACIU consensus from analysts for AC Immune SA?
The overall analyst consensus for ACIU is bullish. Out of 2 Wall Street analysts, 4 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $8.35.
How accurate are ACIU stock price projections?
Stock price projections, including those for AC Immune SA, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 16, 2026 2:02 AM UTC